Introduction
============

Acute kidney injury (AKI) is defined by the Acute kidney injury network (AKIN) as an increase in serum creatinine level (sCr) by more than 50% or 0.3 mg/dL or reduction of urine output to less than 0.5 ml/kg per hour \[[@B1]\]. AKI is a common and serious post operative complication and may occur in up to 50% of all patients undergoing cardiac surgery\[[@B2]\]. AKI is associated with 8% mortality rate compared with 0.9% in non-affected patients and remains a major factor for adverse outcomes \[[@B3]\].

Early measures to prevent postoperative AKI can help decreasing morbidity and mortality in these patients. Serum creatinine concentration and creatinine clearance are delayed and relatively insensitive markers of AKI. More sensitive and rapid markers of renal injury are more helpful for early diagnosis and treatment. Urinary neutrophil gelatinase-associated lipocalin (NGAL), with a molecular weight of 25 kD, is a novel biomarker that increases a few hours after a nephrotoxic or ischemic condition \[[@B3]\]. It has been observed that UNGAL level 2 hours after pediatric cardiac surgery can predict AKI with 100% sensitivity and 98% specificity \[[@B4]\].

Cardiopulmonary bypass (CPB) causes systemic inflammatory response syndrome (SIRS). Pentoxifylline (PTX), a non-specific phosphodiesterase inhibitor, inhibits some pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin -10 \[[@B5]\] and IL-1 \[[@B6]\].

Xanthine Oxidase (XO) is source of free oxygen radicals in the ischemic reperfusion injury. PTX also inhibits XO activity \[[@B7]\]. It can also affect the microcirculatory blood flow and contribute to the attenuation of interstitial inflammation, down regulation of monocyte chemo-attractant protein-1 gene expression, reduction in the expression of mitogenic and profibrogenic genes, and suppression of the proliferation of interstitial fibroblast and glomerulomesangial cells \[[@B8]\]. However, the preclinical data with regard to PTX and AKI seems controversial \[[@B9],[@B10]\]. The effect of PTX in reducing renal injury by measuring sCr and α-1-microglobulin was investigated and ameasuring sCr and beneficial role of PTX on the prevention of kidney injury was observed \[[@B11]\]. Our study aims to investigate the effect of PTX on preventing AKI after coronary artery bypass graft (CABG) surgery, by comparing pre- and postoperative levels of NGAL and serum creatinine.

Material and methods
====================

After informed consent, 28 consecutive adult patients undergoing elective on-pump CABG were enrolled in doubled blind randomized control trial at Tehran Heart Center from January to June 2010. The study protocol was reviewed and approved by the Research Board the Ethics Committee at Tehran Heart Center and study funded by Tehran Heart Center. Exclusion criteria included refusal to sign the consent, Collagen-vascular disease, use of immunosuppressive agents, corticosteroids (\> 3 days), methylxantines, diltiazem or sodium nitroprusside, angiography in the past 7 days, hemorrhagic diathesis and coagulopathy, uncontrolled diabetes mellitus, sepsis, renal failure (sCr \> 2 mg/dl), hepatic failure (AST or ALT \> 40 U/L) or urinary tract infection. The patients were randomly assigned to one of two groups: (A) the control group (placebo), and (B) the intervention group (PTX). All patients received the same anesthetic regimen and routine CPB management. Anesthesia was induced by midazolam (0.05 mg/kg), fentanyl (5 mcg/kg), propofol 2 mg/kg and pancoronium (0.1 mg/kg), and was maintained with propofol infusion (10 mg/kg/h) and additional doses of fentanyl and pancoronium. After induction of anesthesia, PTX (Aventis, Switzerland) was administered as an intravenous (IV) bolus dose of 5 mg/kg over 5 minutes, followed by 1.5 mg/kg/h slow IV infusion up to 3 hours after cessation of CPB pump. In the control group, normal saline was used as placebo. UNGAL was measured by ELISA method after induction of anesthesia and repeated at 3 and 24 hours postoperatively. Danish Bioporto^®^rapid ELISA kits were utilized to measure UNGAL. SCr levels were measured before, 24, 48, 72 and 96 hours after surgery and C-reactive protein (CRP) checked before and 24 hours postoperatively. AKI was considered as 50% or 0.3 mg/dl increase in sCr level following surgery. Demographic characteristics, Euroscore, concurrent risk factors, infused serum volume and the time of intubation were recorded for each patient

Statistical analysis
--------------------

The results are presented as mean ± standard deviation (SD) for the quantitative variables and are summarized by absolute frequencies and percentages for categorical variables. The continuous variables were compared using Student\'s *t-*test or nonparametric Mann-Whitney *U*test in not normally distributed data, categorical variables were compared using *Fisher\'s*exact test since more than 20% of cells with expected count of less than 5 were observed. Normal distribution of data was evaluated by Kolmogorov-Smirnov test. *Pearson\'s*correlation coefficient was also conducted to assess the Linearity degree between the quantitative measurements. The differences between the two groups were evaluated by the two-way repeated-measures analysis of variance (ANOVA) across the all time measurements. In each ANOVA model, time was treated as a within subject factor and group and the interaction term between group and time (Group\*Time) also included in the model.

For the statistical analysis, the statistical software SPSS version 13.0 for windows (SPSS Inc., Chicago, IL) was used. P values of 0.05 or less were considered statistically significant.

Results
=======

Half of the 28 patients undergoing CABG and met the criteria were randomized to receive PTX. Both groups were similar in demographic and pre and intraoperative characteristics. Inotropic and vasopressor drugs were used similarly in both groups during and after surgery; there was no significant difference in their doses and frequency of administration (Table [1](#T1){ref-type="table"}). Number of bypass grafts in the intervention group was 3.14 ± 1.17 compared to 3.36 ± 1.75 in the control group which was not different (*p*= 0.56).

###### 

Demographic and baseline data of the patients

  --------------------------------------------------------------------------
  Variable                       Intervention\   Control\        P-value\*
                                 (n = 14)        (n = 14)        
  ------------------------------ --------------- --------------- -----------
  Male gender (n)                10 (71.4%)      13 (92.9%)      0.32

                                                                 

  Age (year)                     58.86 ± 9.41    57.14 ± 11.43   0.66

                                                                 

  Weight (kg)                    77.71 ± 10.02   82.17 ± 12.59   0.31

                                                                 

  Euroscore (Standard score)     1.86 ± 2.07     2.14 ± 1.79     0.69

                                                                 

  LVEF^1^(%)                     50.00 ± 6.79    49.23 ± 7.31    0.79

                                                                 

  Mean ABP^2^(mm Hg)             60.43 ± 15.32   64.86 ± 8.82    0.35

                                                                 

  CVP (cm H~2~O)                 9.00 ± 3.08     7.50 ± 2.82     0.19

                                                                 

  Baseline sCr level (mg/dl)     0.81 ± 0.15     0.78 ± 0.18     0.56

                                                                 

  Baseline UNGAL level (ng/ml)   10.36 ± 8.61    10.57 ± 3.54    0.93

                                                                 

  Baseline CRP level             0.21 ± 0.12     0.32 ± 0.27     0.20
  --------------------------------------------------------------------------

\* P values \<0.05 were considered as significant.

1\. Left Ventricular Ejection Fraction

2\. Arterial Blood Pressure

3\. Central Venous Pressure

A measurement of UNGAL 3 hours after surgery showed an increase in both groups, but the difference between the groups was not significant (*p*= 0.294). Twenty four hours after surgery, the difference in rising UNGAL levels between the two groups remained insignificant (*p*= 0.587) (Figure [1](#F1){ref-type="fig"}). While comparing ANOVA models, the interaction terms did not reach the significant level in both models (*p*= 0.467 for Creatinine and *p*= 0.759 for NGAL).

![**Comparing UNGAL level before and after CABG between the intervention group and the controls (Median/interquartile range)**.](1749-8090-6-8-1){#F1}

AKI developed overall in 2 (7%) (1 in the intervention group vs. 1 in the control group) and 12(42%) of patients (5(35%) in the intervention group vs. 7(50%) in the control group) 24 and 48 hours after surgery, respectively (*p*= 0.445).

There was a significant difference regarding mean sCr levels 24 and 48 hours postoperatively (*p*= 0.02 and *p*= 0.03, respectively). The level of sCr in 72 and 96 hours was not different between the groups. (*p*= 0.12 and *p*= 0.69, respectively) (Figure [2](#F2){ref-type="fig"}).

![**Comparing sCr level before and after CABG between the intervention group and the controls by median/interquartile range**. Asterisks show significant difference.](1749-8090-6-8-2){#F2}

Overall, the increase in UNGAL was slightly correlated with the emergence of AKI as detected by sCr levels (*Pearson\'s*correlation coefficient r = 0.30). Also, there was no significant difference in 24 h postoperative CRP levels (*p*= 0.56) between the groups. Intubation time was also indifferent (*p*= 0.28). Common side effects of PTX (i.e., bleeding, nausea and vomiting) were not significantly higher in the intervention group than those of the control group (Table [2](#T2){ref-type="table"}).

###### 

Intra- and post operative variables

  Variable                                   Intervention (n = 14)   Control (n = 14)    P-value\*
  ------------------------------------------ ----------------------- ------------------- -----------
  ***Intraoperative***                                                                   
                                                                                         
  Infused serum volume (cc)                  1339.29 ± 203.97        1389.29 ± 284.32    0.59
                                                                                         
  CVP^3^(cm H~2~O)                           9.50 ± 2.76             7.71 ± 2.12         0.67
                                                                                         
  Urine volume (cc)                          1100.00 ± 427.42        1400.00 ± 514.408   0.10
                                                                                         
  Pump time (Minutes)                        63.21 ± 23.69           71.50 ± 20.71       0.33
                                                                                         
  Aortic Clamp time (Min.)                   37.36 ± 14.47           42.36 ± 16.14       0.39
                                                                                         
  Number of Grafts                           3.14 ± 1.17             3.36 ± 0.75         0.56
                                                                                         
  Use of inotropic drugs (No. of patients)   2                       5                   0.32
                                                                                         
  ***Postoperative***                                                                    
                                                                                         
  24-h CVP                                   9.68 ± 1.91             10.29 ± 3.09        0.53
                                                                                         
  24-h mean ABP                              73.09 ± 21.97           80.00 ± 5.99        0.26
                                                                                         
  24-h urine volume (cc)                     3864.29 ± 855.39        3693.93 ± 651.96    0.55
                                                                                         
  Bleeding (3 hours)(cc)                     96.43 ± 88.71           139.29 ± 122.75     0.29
                                                                                         
  24-h bleeding (cc)                         485.71 ± 200.41         500.00 ± 180.81     0.84
                                                                                         
  24-h sCr level (mg/dl)                     0.79 ± 0.18             1.03 ± 0.43         0.02
                                                                                         
  48-h sCr level (mg/dl)                     0.98 ± 0.20             1.17 ± 0.24         0.03
                                                                                         
  72-h sCr level (mg/dl)                     1.04 ± 0.32             0.96 ± 0.24         0.46
                                                                                         
  96-h sCr level (mg/dl)                     1.02 ± 0.23             0.99 ± 0.21         0.69
                                                                                         
  CRP after 24 h                             11.27 ± 3.83            12.16 ± 4.18        0.56
                                                                                         
  3-h UNGAL level (ng/ml)                    11.07 ± 8.63            15.50 ± 10.60       0.23
                                                                                         
  24-h UNGAL level (ng/ml)                   23.64 ± 15.74           26.86 ± 18.97       0.11
                                                                                         
  Mechanical ventilation time (h)            6.91 ± 2.30             8.16 ± 3.61         0.28
                                                                                         
  Length of ICU stay (h)                     43.75 ± 30.89           41.60 ± 31.46       0.63
                                                                                         
  TNG dosage (mg)                            0.31 ± 0.06             0.28 ± 0.02         0.19
                                                                                         
  Heparin (IU/24 h)                          26035.71                ± 28714.29          ± 0.14
                                                                                         
                                             4343.27                 4983.48             

\* P values \<0.05 were considered as significant.

Discussion
==========

Our study aimed to investigate the role of PTX in reducing AKI in patients undergoing CABG by using UNGAL. Although we could not demonstrate a significant difference between the levels of UNGAL of the control and the treatment group, surprisingly we showed a significant difference in 24 and 48 hours sCr. NGAL is a marker of injury, while creatinine is a marker of function and the expected effect would be increase of UNGAL rather than sCr. One explanation may be the size of the sample, which may be insufficient in this case.

AKI is a serious complication after cardiac surgery that occurs in 30% to 50% of all cardiac surgical patients which increases mortality and morbidity and therefore, hospital stay duration \[[@B2],[@B3]\]. Patients with AKI had an eightfold increase in 30-day mortality \[[@B12]\].

In our study, the incidence of AKI was similar to other studies (42% after 48 hours). However, patients with a history of previous renal failure were excluded and enrolled patients had a good physiological and health condition (Euroscore 2). Thus, it seems that the real incidence of AKI among patients who undergo CABG is much higher.

Measuring urine or plasma NGAL of patients in the first hours after CPB in predicting subsequent renal injury is debatable. One study showed that measuring UNGAL level 2 hours after pediatric cardiac surgery can predict AKI with 100% sensitivity and 98% specificity. Other studies showed limited diagnostic accuracy in predicting AKI defined by change in serum creatinine after cardiac surgery \[[@B4],[@B8],[@B13]\]. A recent study on 50 patients with CPB showed a rapid incline in the postoperative UNGAL level, significantly correlated with AKI \[[@B14]\]. We used this biomarker as a rapid detector of AKI and surveyed the effect of PTX but could not find a strong correlation between 3 h and 12 h UNGAL measurements with 24 h and 48 h sCr levels.

Most Patients undergoing cardiac surgical procedures with CPB have SIRS \[[@B15]-[@B17]\] The antioxidant and anti-inflammatory effects of PTX have been showed in many studies \[[@B18],[@B19]\]. PTX has also been reported to exhibit anticoagulation properties by improving red blood cell deformability, decreasing red blood cell aggregation, and inhibiting neutrophil adhesion \[[@B20]\].

The effect of PTX in alleviating the inflammatory process after cardiac surgery has been studied in few randomized controlled studies. Based on their results, patients receiving PTX had lower levels of inflammatory factors and reduced duration of ventilation and better outcome \[[@B21],[@B22]\]. In one study, administrating PTX to elderly CABG surgical patients (age \> 80) showed a significantly less rise of inflammatory factors such as PMN elastase, CRP, IL-6, IL-8 and IL-10 \[[@B21]\].

In another randomized clinical trial, effect of PTX on reducing the inflammatory effect following CPB surgery in 60 patients was studied by administrating either IV infusion of PTX during surgery or normal saline as placebo. Measurements of inflammatory factors (i.e., white blood cell count and differentiation, C-reactive protein, TNF-α and -6) at 6 and 24 hoursIL postoperatively showed a significant reduction in the intervention group compared to the control group\[[@B23]\]. In our study we could not demonstrate significant effect of PTX on CRP in the first 24 hours after surgery.

To our knowledge, this is the first published study that assesses the effect of PTX on preventing AKI by measuring UNGAL. We expected PTX to have a significant effect on reducing UNGAL regarding its anti-inflammatory and antioxidant effects in early postoperative period. However, we could not find such a correlation. This might be due to the small size of our study population, tough we must note the weak correlation of NGAL with sCr in our study.

Serum Creatinine is still a standard method for evaluating renal function. The effect of PTX in reducing renal injury by measuring sCr and a-1-microglobulin was investigated in one study and a beneficial role of PTX on prevention of kidney injury was observed \[[@B11]\]. Our study, confirms this effect of PTX by preventing rise of sCr at 24 and 48 hours. This may be related to other than the anti-inflammatory and antioxidant properties of PTX. We followed-up the changes in the sCr in 72 and 96 hours postoperatively and did not observe any significant change in these measurements.

We also could not find a significant effect of PTX on early outcomes such as intubation time and the duration of ICU stay as other studies claimed \[[@B22]\]. Again, we contribute this to small sample size.

PTX may lead to abdominal discomfort with nausea and vomiting and also has vasodilatory effect that may increase post operative bleeding \[[@B24]\]. There was no difference between the groups regarding homodynamic parameters or bleeding volume. This is an important finding because PTX is not desirably used in cardiac patients due to the fear from hemorrhage.

Study limitations
-----------------

The main limitation of our study is the small number of patients enrolled, which have led to a relatively low study power in finding significant differences between the two study groups. The other limitation is that the UNGAL measurement is less frequent than similar studies. We also measured CRP as an inflammatory indicator, and did not measure changes of inflammatory cytokines that may show the acute anti-inflammatory and antioxidant effects of PTX better than CRP.

Conclusion
==========

In this study, we show that UNGAL has a weak correlation with sCr after cardiac surgery. PTX reduces the rise of UNGAL although not significantly. PTX may have some effect on preventing AKI as determined by attenuation of creatinine rise. In our study, PTX did not increase the risk of bleeding and caused no hemodynamic instability. We suggest future larger studies to show the effect of PTX to prevent end organ damages such as AKI after cardiopulmonary bypass. More clinical trials are needed to fully determine the different aspects of administrating PTX such as standard doses, duration of infusion and its long-term effect on mortality and morbidity.

Key messages
============

• Acute kidney injury (AKI) is a common complication after coronary artery bypass graft.

• Pentoxifylline tends to reduce UNGAL although not significant.

• Pentoxifylline can prevent AKI after cardiac surgery as detected by serum creatinine.
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